医学
ErbB公司
乳腺癌
帕妥珠单抗
癌症研究
癌症
表皮生长因子受体
曲妥珠单抗
计算生物学
生物信息学
内科学
生物
作者
Joshua Z. Drago,Emanuela Ferraro,Nour Abuhadra,Shanu Modi
标识
DOI:10.1016/j.ctrv.2022.102436
摘要
Targeting the HER2 oncogene represents one of the greatest advances in the treatment of breast cancer. HER2 is one member of the ERBB-receptor family, which includes EGFR (HER1), HER3 and HER4. In the presence or absence of underling genomic aberrations such as mutations or amplification events, intricate interactions between these proteins on the cell membrane lead to downstream signaling that encourages cancer growth and proliferation. In this Review, we contextualize efforts to pharmacologically target the ErbB receptor family beyond HER2, with a focus on EGFR and HER3. Preclinical and clinical efforts are synthesized. We discuss successes and failures of this approach to date, summarize lessons learned, and propose a way forward that invokes new therapeutic modalities such as antibody drug conjugates (ADCs), combination strategies, and patient selection through rational biomarkers.
科研通智能强力驱动
Strongly Powered by AbleSci AI